GeoVax Receives U.S. Patent Office Notice of Allowance for Broad-Spectrum COVID-19 Vaccine Design

About this update from Geovax Labs, Inc.

[{"type":"image","caption":"","headline":"GeoVax Highlights 2026 as a Pivotal Year for Progress","size":{"original":{"width":140,"height":140,"url":"https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CK3y_RQaAtNDQGf8lPQXOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc","width":140,"height":140}}},{"type":"text","content":"Patent Strengthens GeoVax's Multi-Antigen Vaccine Platform Designed to Deliver Broader, Longer-Lasting Protection and Support Future Pandemic Preparedness","length":158,"tagName":"p"},{"type":"text","content":"ATLANTA, GA - December 16, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing next-generation vaccines and cancer immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/888,131, titled "Recombinant Modified Vaccinia Ankara (rMVA) Expressing Spike, Membrane, and Envelope Proteins of SARS-CoV-2."","length":465,"tagName":"p"},{"type":"text","content":"This patent protects GeoVax's novel vaccine design that uses its proprietary Modified Vaccinia Ankara (MVA) platform to deliver three key structural proteins of the SARS-CoV-2 virus - Spike (S), Membrane (M), and Envelope (E) - rather than relying solely on the Spike protein, as current mRNA vaccines do. By including multiple antigens, the GeoVax vaccine is designed to trigger a broader and more durable immune response, helping maintain protection even as the virus continues to evolve.","length":494,"tagName":"p"},{"type":"text","content":""This patent allowance is additional validation of our innovative approach to vaccine design," said David A. Dodd, Chairman and Chief Executive Officer of GeoVax. "Our goal has always been to move beyond single antigens delivery technologies with the intention of providing broader, longer-lasting protection - especially for vulnerable populations, such as the immunocompromised, who remain at significant risk despite widespread vaccination."","length":464,"tagName":"p"},{"type":"text","content":"The new patent extends GeoVax's intellectual property portfolio covering its multi-antigen MVA vacci...

More updates from Geovax Labs, Inc.